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Available online at www.sciencedirect.comHuman neurodegenerative and infectious diseases and
tumorigenesis are associated with alterations in ubiquitin
pathways. Over 10% of the genome encode for genes that
either bind or manipulate ubiquitin to affect a large proportion of
biological processes. This has been the basis for the
development of approaches allowing the enrichment of
ubiquitinated proteins for comparisons using proteomics and
mass spectrometry. Tools such as tagged tandem ubiquitin
binding domains, chemically derivatized ubiquitin or anti-gly-
gly-lys antibodies combined with mass spectrometry have
contributed to surveys of poly-ubiquitinated proteins, poly-
ubiquitin linkage diversity and protein ubiquitination sites and
their relation to other posttranslational modifications at a
proteome wide level, providing insights in to how dynamic
alterations in ubiquitination and deubiquitination steps are
associated with normal physiology and pathogenesis.
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Ubiquitin networks in human diseases
The discovery of ubiquitin was made within the context
of experiments on ATP-dependent protein breakdown
and turn-over [1]. Ubiquitin is a small 76 amino acid
protein that is highly conserved across plants, yeast and
mammals. Nearly 1000 enzymes are involved in the
recognition of ubiquitin and its attachment to and clea-
vage from other protein substrates, suggesting that this
posttranslational modification must play a fundamental
role in biology far beyond protein degradation. Ubiquitin
is found to be covalently attached to other proteins either
as poly-ubiquitin chains or mono-ubiquitin, and the
chains consist of linkages through all seven ubiquitin
encoded lysines (lys6, 11, 27, 29, 33, 48 and 63) as well
Open access under CC BY-NC-ND license.www.sciencedirect.com as the N-terminus [2]. Ubiquitin conjugating enzymes
(E3 ligases) of the RING-finger or HECT-type families
appear to specifically create poly-ubiquitin chains of
distinct types (reviewed in [3]). Less is known about
the poly-Ub linkage specificity of deubiquitinating
enzymes (DUBs), but the current view remains that
Ubiquitin C-terminal hydrolases (UCHs) mainly cleave
ubiquitin precursors, whereas ubiquitin specific proteases
(USPs), ovarian tumor containing proteases (OTUs), the
Josephin and the JAB1/MPN/MOV34 (JAMM) proteases
all have a various degree of promiscuity towards different
poly-Ub linkages or cleave mono-ubiquitin from protein
substrates [2,4].
Noncovalent interactions also contribute to the complexity
of ubiquitin signaling. At least 20 different types of
domains have been identified in ubiquitin binding proteins
(UBP) that interact with ubiquitin in a noncovalent manner
to regulate the fate of ubiquitinated proteins [5,6].
It is therefore not surprising that many genes linked to
ubiquitin processing and recognition have been found to
be mutated within the context of human diseases
(Figure 1). Interestingly, neurological disorders appear
to be particularly vulnerable to mutations in ubiquitin
conjugating and deconjugating enzymes. For instance,
mutations in the parkin gene encoding for a E3 ubiquitin
ligase and the uchl1 gene encoding for a ubiquitin C-
terminal hydrolase (UCH-L1) are associated with early-
onset autosomal recessive forms of Parkinson’s disease
[7]. Also, mutations in the E6-AP gene coding for the
ubiquitin ligase E6-AP (UBE3A) are linked to the Angel-
man Syndrome [8], and single point mutations in the
ubiquitin ligase HUWE/Mule/ARF-BP are the cause of
mental retardation syndromic X-linked Turner type
(MRXST), possibly through aberrant DNA repair
[9,10]. In addition, the familial amyotrophic lateral
sclerosis and Machado-Joseph disease/spinocerebellar
ataxia type 3 is directly linked to mutation in a gene
encoding for a deubiquitinating enzyme (Ataxin-3),
which is involved in degradation of misfolded chaperone
substrates via its interaction with STUB1/CHIP [11].
Aberrant expression/mutations of many E3 ubiquitin
ligases and DUBs are also found in diverse cancer types
(reviewed in [12–14]). In some cases, E3 ligases and
DUBs act as tumor suppressors, such as the von Hippel
Lindau vhl gene encoding for an E3 ubiquitin ligase,
where mutations are the underlying cause of suscepti-
bility to pheochromocytoma (PCC) [15]. AnotherCurrent Opinion in Chemical Biology 2013, 17:59–65
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UPS network in human diseases. Schematic representation of human diseases such as cancer, neurodegenerative disorders, inflammation and
microbial infections with links to the ubiquitin system. Many of the underlying molecular mechanisms involving ubiquitin-dependent processes were
discovered using genetic studies and ubiquitin proteomics approaches as described in the text.example is the cyld gene encoding for the deubiquitinase
CYLD, and direct mutation in the protease domain have
been linked to the turban tumor syndrome (cylindroma-
tosis) [16].
These cases as well as many others of this type suggest that
in some way the homeostasis and dynamics of ubiquiti-
nated proteins is altered either as a consequence or poten-
tially as an underlying cause contributing to disease
pathogenesis. Consistent with this, in the case of neuronal
cells, protein aggregates (‘aggresomes’) often contain poly-
ubiquitinated material, a phenomenon associated with a
pathological phenotype. In addition, more subtle changes
in the dynamic ubiquitination status and perhaps stability
or function of key proteins and enzymes, such as HIF1a by
VHL or a-synuclein by parkin may contribute to diseases
such as cancer and neurodegeneration. Therefore, the
importance of further understanding differential ubiquiti-
nation profiles has called for methodologies that allow aCurrent Opinion in Chemical Biology 2013, 17:59–65 comprehensive assessment of the ubiquitination pool
under different physiological and pathological conditions.
Recent advances in proteomics of ubiquitin
and ubiquitin-like proteins
Ubiquitin, ubiquitin-like proteins and poly-ubiquiti-
nated material can be enriched and isolated biochemi-
cally using tagging and affinity-based approaches
(reviewed in [17]). A major leap in the efficiency of
pulling down endogenous poly-ubiquitinated material
from cells was achieved using tagged tandem ubiquitin
binding domain constructs, a concept that has now also
been extended to ubiquitin-like species [18,19]. This
also allows, at least to some degree, an enrichment of
poly-ubiquitin linkage specific species using different
concatenated ubiquitin binding domains. The compli-
cation of multiple poly-ubiquitin chain variations does
represent a challenge for efficient biochemical isolation.
One way to overcome this was to utilise a ubiquitin-K0www.sciencedirect.com
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forward identification of ubiquitinated proteins and
ubiquitination sites, although with potential limita-
tions when using mutated ubiquitin [20]. Recently,
a novel biochemical tool has become available that
allow the specific enrichment of mono-ubiquitinated
and poly-ubiquitinated material from cells without a
bias for either mono-ubiquitin or particular poly-ubi-
quitin linked material. This approach is on the basis of
using monoclonal antibodies that recognize gly-gly
moieties attached to lysine side chains via an isopep-
tide bond, remnants of ubiquitinated proteins or poly-
ubiquitin itself after proteolytic digestion with trypsin
(Figure 2), leading to the identification of 10 000,
11 000, and 19 000 sites by mass spectrometry,
respectively [21,22]. These experiments demonstrate
that the complexity of protein ubiquitination is com-
parable to the complexity of protein phosphorylation,
and that site-specific ubiquitination studies at a pro-
teome-wide level are now feasible [23,24]. Wagner
et al. discovered a non-proteasomal function for almost
half of all identified diglycine sites and also overlaps
between ubiquitinated and acetylated lysine residues
[21]. The study by Kim et al. highlights that a very
significant fraction of ubiquitin conjugates results from
freshly translated proteins and that ubiquitylation is
frequently a substoichiometric  event [22]. TheFigure 2
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www.sciencedirect.com availability of these antibodies has sparked a number
of subsequent proteome-wide ubiquitination studies.
For example, this technology was used to identify
substrates for Cullin-RING ligases [25] and to show
ubiquitination dynamics in DNA-damage signaling
[26] and murine tissues [27]. Also, protein ubiquitina-
tion in synapses of rat brains was also studied using
this approach [28]. Advantages and challenges are also
discussed in recent reviews [24,29].
There are some limitations to this approach in that
there is some ambiguity in assigning gly-gly modifi-
cations on lysine residues to ubiquitination, as for
instance NEDD8 modification also leads to the same
tag present on lysine side chains after proteolytic
trypsin digestion. To overcome this, other tags on
the basis of the detection of LRGG-lysine have been
used in MS experiments (Figure 2). However, this
approach is not feasible for the detection of protein
modifications with other ubiquitin-like proteins, such
as SUMOylation. Recent attempts to overcome this
without the need to introduce SUMO C-terminal
mutations were reported in which the application of
aspartic acid cleavage, caspase, elastase and trypsin
digestion protocols were used to generate SUMO tags
on lysine residues that can facilitate detection of
modifications by SUMO1 and SUMO2/3 [30,31].)
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ere made in creating tools to better assess profiles of ubiquitinated
concatenated ubiquitin binding domain (UBD) constructs such as tetra-
 of poly-ubiquitinated material from cells. (b) Proteome-wide assessment
ted material, the resulting gly-gly modified lysines isolated using anti-gly-
) Active site molecular probes on the basis of the ubiquitin scaffold have
conditions as well as examining the selectivity of small molecule DUB
Current Opinion in Chemical Biology 2013, 17:59–65
62 OmicsSuch approaches permit the survey of a wider range of
ubiquitin and ubiquitin-like modification profiles on pro-
teomes under normal physiological and pathological con-
ditions in the future.
Chemoproteomics targeting ubiquitination
and deubiquitination
Advances in the sensitivity and throughput of mass spec-
trometry (MS) based discovery capabilities have contin-
ued to spur experiments that are focused on
characterising the expression of conjugating (E1/E2/
E3s) and deconjugating enzymes (DUBs), but also their
interactors and/or substrates. For instance, whole cell
proteome studies can now provide insight into the turn-
over and levels of several thousands of cellular proteins in
one single experiment [32,33,34]. Of particular note is
a study reporting on a reference proteomes of 11 cell lines
illustrating differences in the steady state level of aFigure 3
5 
6 
7 
4 
5 
6 
7 
8 
O
TU
B1
 
UC
H-
L3
 
US
P1
4 
US
P5
 
US
P7
 
UC
H-
L5
 
US
P9
X 
US
P9
 
US
P1
0 
US
P1
5 
US
P1
1 
US
P4
8 
US
P4
7 
US
P1
3 
US
P1
6 
US
P2
4 
US
P1
9 
US
P1
9 
US
P8
 
O
TU
D5
 
R
el
at
iv
e 
Ab
un
da
nc
e 
(iB
AQ
) 
R
el
at
iv
e 
Ab
un
da
nc
e 
(iB
AQ
) 
(a)
(b)
RIN
G1
TR
IM
25
RN
F1
81
HU
WE
1
UF
L1
RIN
G1
b
TR
IM
33
BR
E1
A
E6
AP
KC
MF
1
UB
R5
MA
RC
H5
MM
21
TR
AF
6
RN
F2
Proteomic abundance of selected DUBs and E3s in human cells. Whole prote
of intracellular components of the ubiquitin system. As an example, the relati
measured in human embryo kidney (HEK) cells using mass spectrometry an
Current Opinion in Chemical Biology 2013, 17:59–65 number of proteins [32]. This is the first time that
comprehensive information on the abundance of com-
ponents of the ubiquitin system is available in different
cell types. Interestingly, the abundance of ubiquitin-
specific enzymes appears to vary to a great extent as
demonstrated for a selection of E3 ligases and DUBs
(Figure 3). This information can help to better under-
stand their biological function when combined with func-
tional assays, cell type specificity and regulation. Also,
direct co-immunoprecipitation of either E3 ligase com-
ponents or DUBs directly has given better clues about the
enzyme’s function through the discovery of interactors
and/or substrates [35–37]. However, these approaches
have their limitations in terms of the identification of
cognate substrates as often direct enzyme-substrate affi-
nities are low. The emerging availability of small mol-
ecule DUB and E3 ligase inhibitors may offer a way to
overcome these challenges, as large proportions of theVC
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ome analysis in cell lines allows the interrogation of relative abundances
ve abundance of a selection of DUBs (a) and E3 ligases (b) are shown as
d ion based absolute quantitation (iBAQ) as described in [32].
www.sciencedirect.com
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Figure 4
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• Advances  in  proteomics &  mass  spectrometry  allow  proteome-wide
abundance measurem ents of ubiquitin  components 
• Anti-gly-gly tag antibodies have p erm itted the surve y
on a proteome-w ide lev el 
• Chemoproteomics  too ls allow the surve y of active deubiquitinati ng enzym es
and their inhibiti on by s mall molecule inhibi tors 
• Comprehensi ve  comparisons  of  the  dynamics  of  the  poly-ubiquitinated
protein pool exp and the UPS network rel ated to human diseases
of ubiquitination si tes
Summary of main points discussed in this review.ubiquitin pool can now be assessed and compared be-
tween control and cells acutely treated with such com-
pounds, as exemplified with broad and more selective
DUB inhibitors [38,39] and also with E3 ligase inhibitors
([36,40], reviewed in [41]).
Chemical probes for enzymes in the ubiquitin
system
Detailed knowledge of the molecular mechanisms under-
lying ubiquitin processing provided an inroad for design-
ing molecular probes targeting conjugating and
deconjugating enzymes. This approach has regained in-
terest also because it allows small molecule inhibitor
development within the UPS [42]. Whereas ubiquitin
processing enzymes (USPs, UCHs, OTUs) can be readily
profiled using ubiquitin based chemical probes targeting
proteolytic catalysis, the application of this activity-based
approach towards the ubiquitin conjugating cascade has
proven to be challenging [43,44], although chemical
crosslinking was successfully used for HECT domain
E3 ligases [45]. In the case of deubiquitination, further
progress has been made to create molecular probes
mimicking different isopeptide linkages between ubiqui-
tin and protein substrates including ubiquitin itself by
integrating peptides at the P0 side of the scissile bond with
an electrophilic moiety in the center, which appear to
selectively target subsets of DUBs in crude cell extracts
[46]. This approach will complement predominantly in
vitro studies on how DUBs can distinguish between
different poly-ubiquitin chains for processing, currently
achieved using model substrates [47] or fluorescence
resonance techniques [48]. Also, more recent probes on
the basis of the ubiquitin scaffold are now available with
C-terminal fluorescent moieties via ‘Click Chemistry’
[49], or N-terminal fluorescent or photoreactive moieties
through total synthesis [50,51]. Such tools will undoubt-
edly be used to profile ubiquitin processing enzymes such
as DUBs, but also related enzymes specifically recogniz-
ing ubiquitin-like proteins, and thereby contribute to our
understanding the role of these enzymes within the
ubiquitin network in normal physiology as well as disease
pathogenesis (Figure 4).www.sciencedirect.com Conflict of interest
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